查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840883

重症肌無力治療市場按治療層級、給藥途徑、通路和最終用戶分類 - 全球預測 2025-2032

Myasthenia Gravis Treatment Market by Treatment Class, Administration Route, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，重症肌無力治療市場規模將成長 31 億美元，複合年成長率為 5.62%。

關鍵市場統計數據
基準年 2024 20億美元
預計年份：2025年 21.1億美元
預測年份 2032 31億美元
複合年成長率 (%) 5.62%

一個涵蓋臨床選擇、治療路徑和營運壓力的綜合框架，定義了重症肌無力患者的當代護理

重症肌無力的治療模式複雜，臨床表現多樣，治療方法不斷發展，監管環境也十分複雜。患者和臨床醫生必須在眾多治療方案中做出選擇，從乙醯膽鹼酯酶抑制劑等對症治療，到糖皮質激素、非類固醇類抗發炎藥、靜脈注射免疫球蛋白、血漿置換，以及不斷擴展的生物目標等免疫調節療法。本報告整合了臨床、商業和供應鏈等多個視角，揭示了治療策略如何朝著精準治療的方向發展，旨在提高疾病的長期控制率，同時降低累積毒性。

隨著診斷準確性的提高和治療模式轉向針對特定患者群體的早期強化治療轉變，相關人員在治療順序、給藥物流和支付方參與方面面臨新的決策。現今的治療生態系統既包括長期使用的口服藥物，也包括高成本的靜脈注射和皮下注射生物製藥，這需要協調的治療路徑、輸注能力管理和替代分銷方案。因此，本文將探討常見的臨床實踐、應用動態以及對醫療服務提供者、生產商和經銷商的營運影響。

本導言著重闡述可操作的見解，揭示產品選擇的臨床促進因素、限制產品可及性的營運瓶頸，以及影響產品推廣時機的監管和報銷動態。後續章節將圍繞這些主題展開，重點在於闡述投資、夥伴關係和流程再造如何能顯著改善病患預後和提升系統效率。

標靶免疫療法、分散式給藥和新興證據的進展如何重塑臨床實踐中的治療選擇和護理模式

重症肌無力的治療模式正在經歷變革性變化，這主要得益於標靶免疫學創新、便捷給藥方式以及不斷發展的醫療服務模式。標靶補體抑制劑和FcRn定向藥物的出現，拓展了治療手段，使其不再局限於廣譜免疫抑制，使臨床醫生能夠根據免疫抗原性機制和患者表現型製定個性化的治療方案。同時，生物相似藥和新一代抗體計畫的成熟也開始影響籌資策略和治療順序，迫使支付者和醫療服務提供者重新評估藥物製劑和階梯治療方案。

同時，向門診和居家輸液治療的轉變正在重塑患者接受治療的場所，減少了對醫院輸液中心的依賴，並推動了對皮下和居家輸液管理方面的培訓、通路和安全通訊協定的投資。隨著醫療服務從集中式門診服務轉向居家輸液，這種去中心化趨勢影響了藥品分銷管道和藥房夥伴關係。

監管路徑和真實世界證據舉措也是推動這一轉變的關鍵因素。核准後的數據生成和適應症擴展正在使監管機構的預期與支付方的需求保持一致，從而形成一個反饋循環，加速基於循證醫學的標靶治療的應用。總而言之，這些動態正在縮短臨床差異化產品的推廣應用時間，同時提升整合商業化策略的重要性，這些策略應涵蓋臨床教育、供應彈性以及與支付方的協調。

評估2025年關稅調整如何影響重症肌無力治療用生物製藥的供應鏈、籌資策略與臨床進入動態

2025年實施的關稅政策變化所帶來的累積影響正波及整個醫藥供應鏈，尤其對依賴生物製藥（如重症肌無力）影響尤為顯著。關稅引發的進口成本調整迫使生產商和經銷商重新評估其全球採購、製造外包關係以及產能過剩計劃，以確保複雜注射和輸液產品的持續供應。為此，供應鏈領導者正在尋求供應商多元化並增加庫存緩衝，同時採購團隊也在加速推進區域化策略，以降低單一產地生產的風險。

這些政策轉變也促使人們更加關注分銷經濟學。醫院系統和專科藥房不得不調整其合約條款以適應不斷變化的土地成本，一些醫療機構也重新協商了服務協議，以確保能夠持續為重症患者提供服務。支付者和機構採購者也加強了圍繞價格和價值的討論，強調醫療總成本和實際療效是談判的關鍵因素。

在臨床層面，關稅主導的環境促使相關人員更加關注最佳化治療方案，給藥途徑和給藥頻率有時會影響維持病人用藥可及性和控制病人自付費用的決策。監管和貿易政策的不確定性進一步凸顯了情境規劃、可擴展生產和有針對性的臨床傳播策略的重要性，這些策略旨在讓臨床醫生和患者確信，儘管面臨全球貿易逆風，治療的連續性仍然是首要任務。

透過對治療層級、給藥途徑、管道和最終用戶背景進行詳細的細分分析，揭示可操作的臨床和物流決策點。

細分市場層面的動態變化揭示了在設計臨床路徑和商業策略時，治療、物流和通路特定因素如何相互交織。基於治療層級，我們涵蓋了乙醯膽鹼酯酶抑制劑、免疫抑制劑、靜脈注射免疫球蛋白、單株抗體和血漿置換。免疫抑制劑進一步分為糖皮質激素和非類固醇免疫抑制劑，後者分別針對Azathioprine、Cyclosporine和RituximabMycophenolate Mofetil進行單獨分析。單株抗體則專門針對Eculizumab、Ravulizumab和利妥昔單抗進行分析。這種分類有助於明確臨床決策標準：症狀治療與免疫調節治療、長期維持治療與急性搶救治療，以及機制特異性標靶治療與廣譜免疫抑制。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將新生兒Fc受體抑制劑（如efgartigimod）整合到重症肌無力全身型患者的早期治療流程中
  • 由於在難治性全身性重症肌無力患者中取得了積極的臨床試驗結果，對補體 C5 抑制劑的需求正在增加。
  • 新興的雙特異性T細胞銜接器療法可為乙醯膽鹼受體陽性重症肌無力患者提供標靶免疫調節
  • 開發皮下注射免疫球蛋白製劑，以提高慢性重症肌無力患者的依從性和生活品質
  • 擴大遠端醫療監測項目，以促進重症肌無力患者的遠距症狀追蹤和個人化治療調整
  • 產業加大對新型生物標記的投資，以用於重症肌無力的準確嚴重程度評估和個人化治療選擇
  • 生物類似免疫球蛋白產品的激增對品牌靜脈注射療法構成了挑戰，並影響了市場定價趨勢。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 重症肌無力藥物市場（依治療層級分類）

  • 乙醯膽鹼酯酶抑制劑
  • 免疫抑制劑
    • 皮質類固醇
    • 非類固醇免疫抑制劑
      • Azathioprine
      • Cyclosporine
      • Mycophenolate Mofetil
  • 靜脈注射免疫球蛋白
  • 單株抗體
    • Eculizumab
    • Ravulizumab
    • Rituximab
  • 血漿置換

9. 重症肌無力治療市場（依給藥途徑分類）

  • 靜脈
  • 口服
  • 皮下

第10章：重症肌無力藥物市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：重症肌無力治療市場（依最終使用者分類）

  • 診所
  • 居家照護
  • 醫院

第12章：重症肌無力藥物市場區域分析

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：重症肌無力藥物市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：各國重症肌無力藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Alexion Pharmaceuticals, Inc.
    • argenx SE
    • UCB SA
    • Takeda Pharmaceutical Company Limited
    • Sanofi SA
    • Johnson & Johnson
    • Pfizer Inc.
    • Novartis AG
    • CSL Limited
    • Roche Holding AG
Product Code: MRR-0A609A26A9B8

The Myasthenia Gravis Treatment Market is projected to grow by USD 3.10 billion at a CAGR of 5.62% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.00 billion
Estimated Year [2025] USD 2.11 billion
Forecast Year [2032] USD 3.10 billion
CAGR (%) 5.62%

A comprehensive framing of clinical choices, therapeutic pathways, and operational pressures that define contemporary care for patients living with myasthenia gravis

Myasthenia gravis presents a complex therapeutic landscape shaped by heterogeneous disease presentations, evolving treatment modalities, and an increasingly sophisticated regulatory environment. Patients and clinicians navigate choices that range from symptomatic management with acetylcholinesterase inhibitors to immune modulation through corticosteroids, nonsteroidal agents, intravenous immunoglobulin, plasma exchange, and an expanding array of targeted biologics. This report synthesizes clinical, commercial, and supply-chain perspectives to clarify how therapeutic strategies are converging toward precision approaches that aim to improve durable disease control while reducing cumulative toxicity.

As diagnostic accuracy improves and treatment paradigms shift toward earlier intensification for select patient segments, stakeholders face new decisions about sequencing, administration logistics, and payer engagement. The therapeutic ecosystem now includes long-established oral agents alongside high-cost intravenous and subcutaneous biologics, which together demand coordinated care pathways, infusion capacity management, and alternative distribution solutions. Accordingly, the introduction frames prevailing clinical practices, adoption dynamics, and the operational implications for providers, manufacturers, and distributors.

Throughout this introduction, emphasis remains on actionable insight: identifying the clinical drivers of product selection, the operational bottlenecks that constrain access, and the regulatory and reimbursement dynamics that shape adoption timing. The subsequent sections build on these themes to reveal where investment, partnership, and process redesign can yield measurable improvements in patient outcomes and system efficiency.

How advances in targeted immunotherapies, decentralized administration, and evidence generation are reshaping treatment choice and care delivery across clinical settings

The therapeutic landscape for myasthenia gravis is undergoing transformative shifts driven by innovations in targeted immunology, simplified administration modalities, and evolving care delivery models. Targeted complement inhibitors and FcRn-directed agents have expanded the armamentarium beyond broad immunosuppression, enabling clinicians to tailor interventions by immunopathogenic mechanism and patient phenotype. At the same time, maturation of biosimilar and next-generation antibody programs has started to influence procurement strategies and treatment sequencing, prompting payers and providers to re-evaluate formulary placement and step therapy paradigms.

Concurrently, a pivot to outpatient and home-based infusion care is reshaping where patients receive treatment, reducing reliance on hospital-based infusion centers and prompting investment in training, remote monitoring, and safety protocols for subcutaneous and home infusion administration. This decentralization has implications for distribution pathways and pharmacy partnerships as care shifts away from centralized ambulatory services.

Regulatory pathways and real-world evidence initiatives are also key levers in this transformation. Post-authorization data generation and adaptive label expansions are aligning regulatory expectations with payer requirements, creating a feedback loop that accelerates evidence-based adoption for targeted therapies. Taken together, these dynamics are compressing time-to-adoption for clinically differentiated products while heightening the importance of integrated commercialization strategies that address clinical education, supply resilience, and payer alignment.

Assessing how 2025 tariff shifts have pressured biologic supply chains, procurement strategies, and clinical access dynamics for therapies used in myasthenia gravis

The cumulative impact of tariff policy changes implemented in 2025 has reverberated across pharmaceutical supply chains, with particular consequences for biologic-dependent therapeutic areas such as myasthenia gravis. Tariff-induced adjustments to import costs have pressured manufacturers and distributors to reassess global sourcing, contract manufacturing relationships, and redundant capacity planning to preserve continuity of supply for complex injectables and intravenous products. In response, supply chain leaders have increased vendor diversification and invested in inventory buffers, while procurement teams have accelerated regionalization strategies to reduce exposure to single-origin manufacturing risks.

These policy shifts have also prompted greater scrutiny of distribution economics. Hospital systems and specialty pharmacies have had to adapt contracting practices to accommodate altered landed costs, and some providers have renegotiated service agreements to maintain stable access for high-acuity patients. Payers and institutional buyers intensified price and value discussions, emphasizing total cost of care and real-world effectiveness as negotiation anchors.

Clinically, the tariff-driven environment intensified stakeholder focus on treatment choice optimization, where administration route and frequency sometimes influenced decisions designed to preserve access and manage patient out-of-pocket exposure. Regulatory and trade policy uncertainty has further underscored the importance of scenario planning, expandable manufacturing, and targeted clinical communication strategies to reassure clinicians and patients that therapeutic continuity remains a priority despite global trade headwinds.

Detailed segmentation analysis connecting therapeutic classes, administration routes, channels, and end-user contexts to reveal actionable clinical and logistical decision points

Segment-level dynamics illuminate how therapeutic, logistical, and channel-specific considerations intersect when designing clinical pathways and commercial strategies. Based on Treatment Class, the landscape encompasses acetylcholinesterase inhibitors, immunosuppressants, intravenous immunoglobulin, monoclonal antibodies, and plasma exchange, with immunosuppressants further disaggregated into corticosteroids and nonsteroidal immunosuppressants, and the latter examined across azathioprine, cyclosporine, and mycophenolate mofetil, while monoclonal antibodies are analyzed with specific attention to eculizumab, ravulizumab, and rituximab. This taxonomy clarifies clinical decision nodes: symptomatic control versus immune modulation, long-term maintenance versus acute rescue, and mechanism-specific targeting versus broad immune suppression.

Based on Administration Route, therapies are considered across intravenous, oral, and subcutaneous modalities, highlighting trade-offs in patient convenience, infusion resource needs, and monitoring intensity. Based on Distribution Channel, the analysis evaluates hospital pharmacies, online pharmacies, and retail pharmacies to reveal how procurement practices, reimbursement pathways, and controlled-drug handling requirements shape product availability. Based on End User, the report separates clinics, home care, and hospitals to capture differences in staffing, infrastructure, and care coordination needs that influence where therapies are initiated, continued, or transitioned.

By integrating these segmentation lenses, stakeholders can identify which therapeutic classes align with existing care infrastructure, where investments in training or infusion capacity will unlock access, and how distribution partnerships can be structured to support diverse administration settings.

How regional regulatory, procurement, and care-delivery differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape access and adoption dynamics

Regional dynamics materially influence clinical practice patterns, distribution strategies, and regulatory-compliance priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, concentrated centers of excellence and established specialty pharmacy networks support adoption of high-cost biologics, while payer-driven utilization management and reimbursement negotiations shape access pathways and require robust real-world evidence to secure favorable positioning. This region emphasizes integration between tertiary care centers and outpatient infusion capabilities, facilitating earlier use of targeted therapies for well-characterized patient cohorts.

Across Europe, Middle East & Africa, fragmented regulatory and reimbursement environments produce heterogenous adoption curves; centralized health technology assessment processes, country-level formulary decisions, and variable infusion capacity drive differentiated clinical protocols. Stakeholders in this region often prioritize cost-effectiveness analyses and regional manufacturing partnerships to mitigate supply chain exposure and align with public procurement frameworks.

In the Asia-Pacific region, capacity expansion for biologics and rising investment in specialty care infrastructure coexist with diverse regulatory pathways and price sensitivity. Local manufacturing and biosimilar uptake are prominent strategies to increase access, while growing clinical trial activity and real-world data collection create opportunities for evidence generation tailored to regional patient populations. Across all regions, alignment between supply-chain resilience, payer engagement, and clinician education remains central to sustaining access to advanced therapies.

Competitive positioning and partnership playbooks that combine clinical differentiation, distribution capability, and service models to sustain adoption and supply resilience

Competitive dynamics reflect a combination of incumbent biologic manufacturers, emerging targeted therapy developers, and service providers focused on distribution and infusion management. Established companies with complement inhibitors and legacy monoclonal antibody portfolios continue to leverage integrated commercial teams, clinician relationships, and durable manufacturing footprints to support product availability and clinical adoption. Simultaneously, newer entrants that advance FcRn modulation and next-generation antibody formats emphasize differentiated clinical data, dosing convenience, and value communication to payers and providers.

Service-oriented organizations and specialty pharmacies have become critical partners in enabling home and outpatient administration, offering training, remote monitoring, and patient support programs that reduce the burden on hospital infusion centers. Contract manufacturing organizations and regional fill-finish sites play an increasingly strategic role in mitigating trade-related disruptions by offering localized capacity and flexible production scheduling.

Across the competitive set, companies that align clinical differentiation with pragmatic delivery solutions-such as lower-frequency dosing, simplified storage needs, or subcutaneous formulations-are better positioned to influence treatment algorithms and secure inclusion in institution-level formularies. Successful commercial strategies increasingly combine robust post-authorization evidence plans with targeted investments in channel partnerships that ensure both clinical uptake and operational sustainability.

Actionable steps for manufacturers and providers to align evidence generation, supply redundancy, channel integration, and value-based engagement for durable access

Industry leaders can translate insight into operational advantage by coordinating clinical evidence programs, supply resilience initiatives, and stakeholder engagement tactics. First, align clinical-development timelines with pragmatic evidence generation: complement controlled trial data with real-world studies that address payer and clinician questions about durability, safety in diverse populations, and comparative effectiveness across existing standards of care, thereby strengthening value propositions used in reimbursement discussions.

Second, invest in supply-chain redundancy and regionally distributed manufacturing or fill-finish agreements to reduce exposure to trade policy fluctuations and to support predictable delivery for high-acuity therapies. This should be paired with flexible contracting that accounts for administration-site shifts from hospitals to home or clinic settings. Third, design commercialization approaches that prioritize channel integration: partner with hospital pharmacies, specialty and online pharmacy providers, and home-infusion service vendors to create seamless patient journeys that reduce administrative burden and improve adherence.

Finally, adopt proactive payer engagement and pricing strategies that emphasize total cost of care and patient-centric outcomes, and prepare tailored economic models that reflect real-world utilization patterns. By synchronizing clinical, operational, and commercial levers, leaders can improve access, reduce treatment disruptions, and create defensible positioning in an increasingly competitive therapeutic arena.

A rigorous mixed-methods approach combining clinician interviews, operational site assessments, and evidence synthesis to ensure actionable and verifiable conclusions

This analysis synthesizes primary and secondary inputs to ensure conclusions are grounded in clinical practice and operational reality. Primary research included structured interviews with neurologists, infusion center directors, specialty pharmacy leaders, regulatory experts, and payer representatives to capture frontline perspectives on treatment selection, administration logistics, and reimbursement hurdles. These conversations were complemented by site visits and protocol reviews that clarified the operational implications of shifting care from inpatient settings to outpatient and home-based models.

Secondary research drew on peer-reviewed literature, regulatory filings, clinical trial registries, and public policy documents to map therapeutic mechanisms, approved indications, and label requirements. Supply-chain and trade policy assessments used customs guidance and industry analyses to evaluate tariff impacts and sourcing strategies. Data triangulation combined qualitative insights with operational metrics to validate hypotheses about distribution channel performance, staffing constraints for infusion services, and barriers to home-based administration.

Limitations include variability in regional practice patterns and the evolving evidence base for newer agents, which necessitates ongoing monitoring of post-authorization data and payer decisions. To mitigate these constraints, the methodology emphasizes iterative stakeholder engagement and recommends periodic updates to reflect emerging clinical data, regulatory actions, and trade-policy developments.

Concluding synthesis that ties therapeutic innovation to practical execution imperatives required for sustained patient access and system-level value

The landscape of treatment for myasthenia gravis is defined by a convergence of clinical innovation, evolving delivery models, and logistical complexity. Targeted biologics and novel immunomodulatory strategies offer the potential for more precise disease control, yet their value is realized only when paired with robust distribution strategies, adaptable infusion capacity, and payer-aligned evidence packages. Trade policy dynamics and regional regulatory heterogeneity add further layers of operational complexity that stakeholders must actively manage.

Ultimately, success in this therapeutic area depends on integrating clinical differentiation with practical execution: aligning dosing and administration characteristics to provider workflows, ensuring supply-chain redundancy to safeguard continuity, and generating the real-world evidence that resonates with payers and clinicians. Cross-functional collaboration-spanning clinical development, supply chain, market access, and channel partners-will be essential to translate therapeutic promise into sustained patient benefit.

As care models continue to decentralize and as new mechanisms of action emerge, stakeholders that anticipate operational challenges and structure flexible, evidence-driven engagement strategies will be best positioned to expand access while maintaining programmatic and financial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of neonatal Fc receptor inhibitors like efgartigimod into early-line treatment algorithms for generalized myasthenia gravis patients
  • 5.2. Rising demand for complement C5 inhibitors driven by favorable clinical trial results in refractory generalized myasthenia gravis populations
  • 5.3. Emergence of bispecific T cell engager therapies offering targeted immunomodulation in acetylcholine receptor positive myasthenia gravis
  • 5.4. Development of subcutaneous immunoglobulin formulations enhancing patient adherence and quality of life in chronic myasthenia gravis management
  • 5.5. Expansion of telehealth monitoring programs to facilitate remote symptom tracking and individualized treatment adjustments in MG patients
  • 5.6. Increasing industry investment in novel biomarkers for precise disease severity assessment and personalized therapy selection in myasthenia gravis
  • 5.7. Growing proliferation of biosimilar immunoglobulin products challenging branded intravenous therapies and influencing market pricing dynamics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Myasthenia Gravis Treatment Market, by Treatment Class

  • 8.1. Acetylcholinesterase Inhibitors
  • 8.2. Immunosuppressants
    • 8.2.1. Corticosteroids
    • 8.2.2. Nonsteroidal Immunosuppressants
      • 8.2.2.1. Azathioprine
      • 8.2.2.2. Cyclosporine
      • 8.2.2.3. Mycophenolate Mofetil
  • 8.3. Intravenous Immunoglobulin
  • 8.4. Monoclonal Antibodies
    • 8.4.1. Eculizumab
    • 8.4.2. Ravulizumab
    • 8.4.3. Rituximab
  • 8.5. Plasma Exchange

9. Myasthenia Gravis Treatment Market, by Administration Route

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Myasthenia Gravis Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Myasthenia Gravis Treatment Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Myasthenia Gravis Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Myasthenia Gravis Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Myasthenia Gravis Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Alexion Pharmaceuticals, Inc.
    • 15.3.2. argenx SE
    • 15.3.3. UCB S.A.
    • 15.3.4. Takeda Pharmaceutical Company Limited
    • 15.3.5. Sanofi S.A.
    • 15.3.6. Johnson & Johnson
    • 15.3.7. Pfizer Inc.
    • 15.3.8. Novartis AG
    • 15.3.9. CSL Limited
    • 15.3.10. Roche Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MYASTHENIA GRAVIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CYCLOSPORINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY NONSTEROIDAL IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN MYASTHENIA GRAVIS TREATMENT MARKET SI